Propylene Glycol-Containing Peptide Formulations which are Optimal for Production and for Use in Injection Devices
US-2019231876-A1 · Aug 1, 2019 · US
Semaglutide in medical therapy
US12029779B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12029779-B2 |
| Application number | US-202016844552-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 9, 2020 |
| Priority date | Oct 12, 2017 |
| Publication date | Jul 9, 2024 |
| Grant date | Jul 9, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to semaglutide for use in weight management.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for reducing body weight of a subject in need thereof, comprising administering semaglutide subcutaneously to the subject in an amount of about 2.4 mg weekly. 2. The method according to claim 1 , wherein the semaglutide is administered once weekly. 3. The method according to claim 1 , wherein the subject is overweight. 4. The method according to claim 1 , wherein the subject suffers from obesity. 5. The method according to claim 1 , wherein the subject has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnoea, and urine incontinence. 6. The method according to claim 5 , wherein the subject has type 2 diabetes mellitus. 7. A method for reducing body weight of a subject in need thereof, comprising administering semaglutide subcutaneously to the subject in an amount of 2.4 mg once weekly. 8. The method according to claim 7 , wherein the subject is overweight. 9. The method according to claim 8 , wherein the subject has type 2 diabetes mellitus. 10. The method according to claim 7 , wherein the subject is suffering from obesity. 11. The method according to claim 10 , wherein the subject has type 2 diabetes mellitus. 12. The method according to claim 7 , wherein the subject has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, dyslipidemia, sleep apnea, and urine incontinence. 13. The method according to claim 1 , wherein the subject is overweight and has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, and dyslipidemia. 14. The method according to claim 7 , wherein the subject is overweight and has at least one weight-related comorbid condition selected from the group consisting of hypertension, type 2 diabetes mellitus, and dyslipidemia.
Assignees
Inventors
Classifications
- A61P3/04Primary
Anorexiants; Antiobesity agents · CPC title
- A61K38/26Primary
Glucagons · CPC title
Dispersions; Emulsions · CPC title
Solutions {(composition of solutions A61K47/00)} · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12029779B2 cover?
- The present invention relates to semaglutide for use in weight management.
- Who is the assignee on this patent?
- Novo Nordisk As
- What technology area does this patent fall under?
- Primary CPC classification A61P3/04. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jul 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).